Woburn, MA International life sciences firm Minovia Therapeutics is expanding its U.S. operations from Kendall Sq. in Cambridge to include a 4,600 s/f facility in the local growing technology cluster. The venture-backed company is slated to commence its GMP cell therapy manufacturing at 12 Gill St., a Cummings Properties building, this fall. Senior leasing director Rob Yacobian of Cummings Properties worked with Cushman & Wakefield executive managing director Ted Lyon on the lease.

“The location and existing buildout of the space make it ideal for Minovia’s operations,” said Minovia Therapeutics owner’s representative Ed Dondero.

“A growing number of urban firms are realizing that a thriving science hub and significant cost savings await them along the 128 belt just north of the city,” said Yacobian. “The Gill St. site offers Minovia a convenient, visually appealing setting in an established biotech community that continues to evolve.”

Among the life sciences firms located at 12 Gill St. are ReForm Biologics, Unchained Labs, and Farcast Biosciences. Other new neighbors in the industry include Amgen, Azurity Pharmaceuticals, Covaris, Bio2 Technologies, Genturi, Modular Genetics, and Verdox. 

Minovia’s new space will include a mix of office and lab space. The firm is constructing a state-of-the-art pharmaceutical clean room in the suite.